Introduction
This review follows the progression of an exploratory discovery to a predictive biomarker over 8 years, during which genomic technology improved dramatically. The initial retrospective, exploratory studies described a new genetic association, HLA-B*5701, with an adverse event (abacavir hypersensitivity or ABC HSR) that affects 2-9% of ABC-treated patients. In this paper, we trace the history of the pharmacogenetic (PGx) investigation of ABC HSR that recently culminated in a prospective clinical trial whose results clearly demonstrate the utility of PGx screening in reducing the risk of HSR among patients prescribed ABC. In doing so, our goal is to provide a longitudinal view of the research project (Table 1) , through a time of significant technical advancement in genetic science, to the present situation where screening is used to prevent potentially serious adverse events before patients are exposed to the drug.
Abacavir is a nucleoside analogue inhibitor of HIV reverse transcriptase developed by GlaxoSmithKline (GSK) for use in multidrug regimens for the treatment of HIV-1 infection. It is currently available as a single active moiety in Ziagen tablets and solution, and in combination with other antiretroviral medicines (Trizivir tablets, Kivexa/Epzicom tablets) and, in parts of the developing world, as generic equivalents to the branded products. ABC is a highly effective HIV treatment and is generally well tolerated. However, approximately 2-9% of patients receiving ABC develop HSR to the drug that requires permanent discontinuation. 1 Abacavir hypersensitivity is an idiosyncratic reaction: it is a relatively dose-independent adverse event and was not predicted in animal models. ABC HSR most often appears within the first 6 weeks of therapy and is manifested by the onset of multiple symptoms, including fever, rash, constitutional, gastrointestinal and/or respiratory symptoms. 1, 2 Clinical management includes immediate and permanent discontinuation of ABC and supportive therapy as required. Death may occur if dosing is continued or if ABC is reintroduced after discontinuation (rechallenge reaction). The diagnosis of ABC HSR is complicated by variable presentation, nonspecific signs and symptoms and, importantly, concomitant use of antiretroviral medications with overlapping adverse event profiles. 3, 4 There was good rationale to hypothesize that ABC HSR was a genetically determined reaction. As with other idiosyncratic reactions, only a minority of patients develop HSR, indicating that individual characteristics were critical for the risk of HSR. Second, initial epidemiologic analyses of clinical trial data identified racial differences in risk for ABC HSR. 2, 4 5 and received full marketing approval in Europe in 1999. Traditional approval in the United States followed, based on durable suppression of plasma HIV-1 RNA for up to 48 weeks. GSK agreed with regulatory authorities to conduct post-approval research to further understanding of ABC HSR. As part of a comprehensive risk-management program for ABC HSR, GSK initiated internal research projects and external collaborations to investigate the epidemiology, immunology, biochemistry and PGx of ABC HSR.
As part of the clinical risk-management program, a risk factor analysis of 5332 patients exposed to ABC in GSK clinical studies compared demographic, clinical and laboratory characteristics of patients who developed ABC HSR with those who did not. Prognostic risk factors for ABC HSR were anti-retroviral treatment status (that is, prior HIV drug treatment) and black race, with both resulting in a lower ABC HSR rate compared with the overall incidence of HSR. 6 Subsequent clinical risk factor analyses conducted on larger data sets have confirmed a decreased risk of ABC HSR for patients of black race and an increased risk of ABC HSR following implementation of a standardized case report form/data collection module for ABC HSR (possibly increasing the false-positive ABC HSR reporting rate, discussed in greater detail below). 4 Initiation of a PGx experiment: can PGx markers associated with ABC HSR be identified?
While the risk factor analyses gave strong evidence that some patient groups may be at somewhat increased or decreased risk for developing ABC HSR, these analyses could not quantify an individual's risk. Therefore, in 1999, GSK initiated a retrospective clinical study, CNA30027, in clinically diagnosed ABC HSR 'cases' and ABC-tolerant patients ('controls') in an attempt to identify PGx markers that may be associated with risk of ABC HSR and improve the benefit-to-risk ratio of ABC. While the European Agency for the Evaluation of Medicinal Products (EMEA) had requested GSK to develop 'diagnostic tests for ABC HSR,' GSK had significant medical concerns that a high-accuracy test was not achievable and an underperforming test might inadvertently put patients at risk for experiencing a rechallenge reaction if ABC was inappropriately reinitiated following a clinically suspected ABC HSR. Instead, GSK's PGx research objective has always been the identification of prognostic markers for ABC HSR for prospective use (that is, prior to the initiation of ABC) as an adjunct to clinical vigilance.
In study CNA30027, patients provided written informed consent and a blood sample for PGx research; details on the previous ABC HSR were collected. No ABC was administered.
As GSK had no preliminary data with which to determine study sample size, initial estimates were calculated by comparing hypothetical differences in allele frequencies between cases and controls. However, owing to the wide range in resulting sample size estimates and the lack of knowledge as to the expected allele frequencies, the clinical team ultimately based the study's recruitment targets on the expected feasibility of patient enrollment. At the end, a sample size of 100 clinically diagnosed cases and 200 matched controls recruited from patients who had previously participated in the GSK ABC clinical development program was selected. The majority of patients who reported ABC HSR were enrolled in GSK's ABC Expanded Access protocol, which allows patients the opportunity to gain access to medicines prior to regulatory approval. 7, 8 Because the symptoms of ABC HSR overlap with those of adverse events associated with other anti-retroviral HIV medicines or other clinical conditions, establishing the accuracy of the clinical diagnosis of ABC HSR was challenging. Furthermore, during the conduct of the ABC Expanded Access protocol, GSK's understanding of HSR grew and guidance to investigators for the diagnosis and management of HSR evolved. It is likely that a significant percentage of cases included in the GSK ABC HSR database were, in fact, non-HSR events that shared some of the symptoms typically attributed to ABC HSR. Very few PGx samples were collected from ABC HSR patients who had experienced a positive rechallenge reaction, as rechallenge was generally prohibited in clinical studies. However, some patients with a previous HSR were inadvertently restarted on ABC. The positive rechallenge definitively diagnosed ABC HSR for these patients.
The search for predictive PGx markers included two experimental approaches. Using the first approach, 150 PGx markers in 12 candidate genes or gene families implicated in immune response and drug metabolism were investigated. A second phase of experimentation, genomewide single-nucleotide polymorphism (SNP) genotyping, was proposed contingent on genotyping technologies advancing sufficiently during the course of the PGx research. Because of slow patient enrollment in study CNA30027, which was predominantly comprised of white male patients, an interim analysis was undertaken. In July 2001, GSK identified statistical associations between multiple major histocompatibility complex (MHC) markers and clinically diagnosed ABC HSR. Among the markers, the strongest statistical association was with HLA-B*57 (subsequently refined to HLA-B*5701 using high-resolution human leukocyte antigen (HLA) genotyping). In the final data set, among self-reported white patients, HLA-B*5701 was more common among patients who had experienced clinically suspected ABC HSR (36 of 65 cases, 55%) than among ABC-tolerant patients (1 of 80 controls, 1%) ( Table 2) . 9 Independently, Dr Simon Mallal, an HIV researcher from Perth, Australia, identified the association between HLA-B*5701 and ABC HSR in his Western Australian HIV cohort (Table 2) . 10 In his study, Dr Mallal reported that the sensitivity of HLA-B*5701 was 78% and the specificity was 98%. Case ascertainment for this HIV cohort was based on review of medical records by a single physician at a single center. Thus, it was likely that the case phenotype in the Western Australian study was less variable than that in the GSK study and the underlying racial heterogeneity of the Western Australian patient population was reduced compared to GSK's US patient population.
Not only were multiple PGx markers identified in genes implicated in immune response but the hypothesis that susceptibility to ABC HSR might have a genetic component was bolstered by a case report published in October 2001 of a white, HIV-1-infected man and his 9-year-old, HIV-infected daughter who received ABC and both experienced clinically diagnosed ABC HSR.
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Because the association between HLA-B*5701 and ABC HSR was identified in a predominantly white male study population and given that the HIV pandemic disproportionately affects non-white patient populations, GSK initiated a second, larger, retrospective PGx study on ABC HSR, study CNA30032, in late 2001 to determine if the HLA-B*5701 association could be generalized to diverse patient populations. Study CNA30032 aimed to enroll 400 clinically diagnosed ABC HSR cases and 400 matched controls with efforts employed to recruit women and non-white patients enrolled in clinical studies conducted by GSK or other researchers, or from private medical practices. To ensure the ABC HSR phenotype was as accurate as possible, in both CNA30027 and CNA30032, the diagnosis of ABC HSR was made by the investigator or treating clinician, after which the ABC HSR data were reviewed by a GSK project physician for consistency with the standard case definition of HSR prior to final designation of a subject as a 'case.' Furthermore, case reports form data collected on all identified 'cases' from CNA30032 were rereviewed by another GSK physician. Based on this second review, all 526 cases enrolled in CNA30032 were categorized as 'definite/probable' (n ¼ 385), 'possible' (n ¼ 115) or 'not a case' (n ¼ 26). Any identified discrepancies between the first and second case reviews were discussed and agreed by a panel of GSK project physicians. The 'standard' case definition included 'definitive/probable' and 'possible' cases, but excluded subjects no longer considered to be cases following GSK project physician rereview. A second 'restrictive' case definition was limited to cases that satisfied the 'definite/ probable' criteria and, additionally, did not receive concurrent non-nucleoside reverse transcriptase inhibitor therapy, a potential confounder to the diagnosis of ABC HSR due to the time to onset and adverse events associated with this class of medicine. 3, 4 In CNA30032, the association between HLA-B*5701 and ABC HSR was replicated in white male subjects and identified in white female subjects. 12 A weaker statistical association was observed in patients who reported their ethnicity as Hispanic. HLA-B*5701 was not significantly associated with ABC HSR when the black standard cases were analyzed, whereas a modest statistical association was detected when the restrictive ABC HSR case definition was used. The allele frequency of HLA-B*5701 varies between racial populations; in US Caucasians, the HLA-B*5701 allele frequency varies between 1.9 and 4.5%, whereas it varies between 1.1 and 2.4% in US African Americans. 13 Results obtained by analyzing data combined from GSK's two retrospective case-control studies (CNA30027 and CNA30032) plus PGx substudies from three clinical trials also initiated during this period, CNA30021, CNA30024 and EPV40001 (the latter, a safety and efficacy study conducted in Thailand), are summarized in Table 3 . HLA-B*5701 was statistically associated with ABC HSR in self-reported white, Hispanic and Thai analysis populations. A modest statistical association (P ¼ 0.041) was observed in a black restrictive population (comprised of 40% of the cases included in the black standard data set; data not shown). HLA-B*5701 was not statistically significantly associated with ABC HSR in the larger black standard population. While the statistical association between HLA-B*5701 and ABC HSR was particularly strong in white subjects, HLA-B*5701 was only present in 50% of white cases. Similarly, HLA-B*5701 was present in 22% of Hispanic cases and in 57% of Thai cases.
Feedback from HIV clinicians: how predictable do PGx markers for ABC HSR need to be?
In 2002, at the time the association between HLA-B*5701 and ABC HSR was replicated, a physician survey was conducted among HIV physicians in the United States, United Kingdom, France, Italy and Spain. The findings suggested that PGx marker(s) with the targeted performance characteristics (95% sensitivity/95% specificity) were unlikely to influence physician behavior to integrate History of abacavir hypersensitivity PGx
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prospective PGx screening into their management of patients treated with ABC. HIV physicians who prescribed ABC for their patients expressed confidence in their ability to diagnose and manage ABC HSR and did not foresee an important role for PGx screening. The marker most highly associated with ABC HSR, HLA-B*5701, failed to achieve the targeted performance characteristics necessary for physician acceptance, within any single racial population (let alone across racial populations), so GSK turned to a genome-wide experimental approach to search for additional PGx markers associated with ABC HSR.
Genome-wide experimental approach to ABC HSR
The inability of HLA-B*5701 or other candidate gene markers to sufficiently account for a patient's risk of experiencing clinically diagnosed ABC HSR led GSK to initiate the second phase of this PGx investigation, a genome-wide strategy utilizing SNPs. 14 This mechanismindependent, genome-wide experiment was initiated in 2002 before the commercial availability of the platforms now commonly used for genome-wide association studies of 100 000-500 000 þ markers and GSK faced the now-obsolete question of whether it was preferable to genotype many markers (100 000s) in a few samples or fewer markers in many samples. Employing both experimental approaches, approximately 105 000 SNPs were genotyped using samples from B300 individual subjects and approximately 1.7 million SNPs were genotyped using pooled DNA samples from these same cases and controls in collaboration with Perlegen Sciences. An independent set of PGx samples of white patients from study CNA30032 was reserved for marker replication. Numerous markers exhibited statistical association with ABC HSR, with approximately 80 markers subsequently replicated in the reserved samples from white patients. The vast majority of these replicated markers were located within the MHC region of the genome. Unfortunately, no individual PGx marker satisfied the target marker performance criteria. In fact, very few of the replicated markers identified in white subjects were statistically associated with ABC HSR in self-reported black or Hispanic analysis populations. Therefore, interrogation of markers that might be uniquely predictive of ABC HSR in black and/ or Hispanic patients was undertaken, despite limitations in sample sizes. No individual marker, marker pair or more complex marker combination was significantly superior to the performance characteristics of HLA-B*5701 alone and, therefore, for no racial group did any marker or marker combination possess the target sensitivity and specificity.
External PGx investigation of ABC HSR
By late 2004, research aimed at identification of PGx markers associated with ABC HSR had also been conducted and published by two external research groups-the Western Australian cohort 10 and the Liverpool UK case-control population. 15 The design and results of the Liverpool study were similar to those of the GSK studies and suggested that HLA-B*5701 screening was cost-effective in Caucasians. 15 The majority of patients were white, the sensitivity of HLA-B*5701 was 51% and ABC HSR case ascertainment was based on clinical symptoms. 15 In the single-center Western Australian clinic, the sensitivity of HLA-B*5701 was 78% and increased to 94% when case ascertainment was supplemented with ABC skin patch testing. 16 ABC skin patch testing will be described in more detail below.
GlaxoSmithKline and its HIV clinical collaborators now believe that differences in case criteria/definitions are likely the major contributor to differences in HLA-B*5701 sensitivity estimates among studies. Only those patients who experience ABC HSR upon drug rechallenge can be considered definitive cases; however, rechallenge with ABC is contraindicated due to the high risk of serious outcomes.
How accurate is the diagnosis of ABC HSR when based on clinical symptoms alone?
In several double-blind clinical trials that included ABC, the incidence of clinically suspected ABC HSR was 2-7% in the treatment arms that did not include ABC, suggesting significant over-reporting of ABC HSR occurs in the clinical trial setting by experienced HIV clinicians. [17] [18] [19] While physician vigilance in monitoring for ABC HSR symptoms is appropriate and reassuring from a patient safety perspective, these data suggest that GSK's collection of ABC HSR cases for its PGx research may include many 'cases' that did not experience ABC HSR. Inclusion of 'non-cases' in PGx studies results in lower estimates of sensitivity for any identified PGx markers, including HLA-B*5701. Abbreviations: ABC, abacavir; CI, confidence interval; GSK, GlaxoSmithKline; HLA, human leukocyte antigen; HSR, hypersensitivity; NPV, negative predictive value; PPV, positive predictive value. Includes subjects from GSK studies CNA30027, CNA30032, CNA30021, CNA30024 and EPV40001.
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One intriguing research tool was developed during the conduct of this PGx research, ABC skin patch testing, which appears to aid in the identification of patients who experience ABC HSR (and reduces the contribution of overdiagnosis of ABC HSR). ABC skin patch testing involves the application of ABC in an inert medium to the surface of the back or upper arm of patients who have experienced a previous clinically suspected ABC HSR. 20, 21 Patches are removed 24 and 48 hours following application. A positive cutaneous reaction (including erythema, induration and pruritis) at the patch test site is consistent with an immunological reaction that is largely similar to cutaneous symptoms associated with the original ABC HSR. A positive skin patch test result has been shown to closely correlate with the clinical diagnosis of ABC HSR and with the presence of the HLA-B*5701 allele. Thus, positive skin patch testing may more precisely define patients who experienced ABC HSR without the risks associated with ABC rechallenge and, therefore, permit a more accurate assessment of the performance characteristics of HLA-B*5701 (or any other PGx marker) and ABC HSR. ABC skin patch testing as a diagnostic cannot be fully validated, as it requires reinitiation of ABC in skin patch test-positive and skin patch testnegative patients previously diagnosed with clinically suspected ABC HSR, a potentially hazardous situation and contraindicated per product labeling.
Meanwhile, although formal evaluation of the clinical utility of prospective HLA-B*5701 screening, especially in non-white patients, had yet to be conducted, several HIV clinicians initiated HLA-B*5701 screening in their own practices. Prospective assessments of HLA-B*5701 screening as a tool to reduce risk for ABC HSR were first reported in Australia 22 and Europe 23, 24 and indicated that PGx screening reduced the incidence of ABC HSR in these single-center cohorts. More recently, some US HIV physicians have implemented HLA-B*5701 screening. LabCorp, a major centralized clinical laboratory in the United States with extensive expertise in HLA genotyping, developed an HLA-B*5701 assay in response to a request from HIV health-care providers. 25 While prospective HLA-B*5701 screening significantly reduced the rate of ABC HSR in these three published reports, these studies raised some important concerns for GSK, assuming the link between HLA-B*5701 and ABC HSR to be true. First, two subjects in the Western Australian cohort who were HLA-B*5701 positive experienced ABC HSR because the subjects' HLA-B genotype results were not reviewed prior to initiation of ABC. 22 Second, in the report from the Brighton UK clinic, the apparent carriage rate of HLA-B*5701 was unexpectedly high compared to the reported carriage frequency of HLA-B*5701 in the general UK population. 23 This led to exclusion of numerous 'HLA-B*5701' putatively positive patients from ABC treatment. Upon further investigation, it became apparent that the clinical laboratory responsible for HLA-B*5701 determination used DNA probes that failed to discriminate between the HLA-B*5701 and HLA-B*5703 alleles. (Note: HLA-B*5703, an allele present in patients of African descent, is not associated with ABC HSR.) Thus, identification of clinical laboratories with robust DNA methods for HLA-B*5701 determination is critical. Finally, along with their experience with prospective HLA-B*5701 screening prior to ABC initiation, Zucman et al. 24 report their experience with reinitiation of ABC therapy in patients who had clinically diagnosed ABC HSR but whose HLA-B*5701 status was retrospectively determined. In five HLA-B*5701-negative patients with a history of 'mild' symptoms, ABC therapy was reinitiated-fortunately all subjects tolerated ABC without evidence of ABC HSR rechallenge reaction. However, as GSK has responsibility for the medical governance of ABCcontaining products, it is important to emphasize the inappropriateness of using a patient's HLA-B*5701 status as the basis for reinitiation of ABC, due to potentially lifethreatening or fatal rechallenge reactions.
ABC HSR PGx data: what's new?
With ABC skin patch testing now available as a research tool for refining case ascertainment and with single-center studies implementing HLA-B*5701 screening in the absence of definitive results, GSK sought to initiate additional clinical studies to address important unanswered research questions. In 2006, GSK initiated two clinical studies aimed at investigation of the predictive value of HLA-B*5701 in white subjects and other racial populations; in an effort to improve the accuracy of ABC HSR case identification, skin patch testing was incorporated as a research tool.
The first study, PREDICT-1 (CNA106030), evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of ABC HSR in more than 1900 ABC-naive, HIV-1-infected adults. 26 The PREDICT-1 study design is illustrated in Figure 1 . Patients were randomized 1:1 to the prospective PGx screening arm or to the current standard of care arm. Patients in the PGx screening arm who were HLA-B*5701 positive were excluded from study participation. All other patients were treated with an ABC-containing regimen for 6 weeks in a double-blind manner (neither physicians nor patients knew the study arm assignment) and were monitored for ABC HSR symptoms. The incidence of ABC HSR was compared between the two study arms for each of two primary end points, clinically diagnosed ABC HSR (that is, physician diagnosis of HSR based on reported symptoms) and immunologically confirmed ABC HSR defined as clinically diagnosed ABC HSR plus a positive ABC skin patch test result.
Among enrolled study subjects, 85% of whom were of selfreported white race, the overall carriage frequency for HLA-B*5701 was 5.6%. Prospective HLA-B*5701 screening reduced the overall incidence of clinically diagnosed ABC HSR from 7.8% in the standard of care control arm to 3.4% in the PGx screening arm (Figure 2, Po0.0001 ). There were 23 immunologically confirmed ABC HSR cases (2.7%) in the standard of care arm compared to zero cases of immunologically confirmed ABC HSR (0%) in the PGx screening arm (Po0.0001). The sensitivity of HLA-B*5701 for clinically diagnosed ABC HSR was between 45 and 50% in both selfreported white subjects and the entire study population; these are similar sensitivity estimates as observed in GSK's retrospective PGx studies. When clinical diagnosis was augmented by skin patch testing, the sensitivity of HLA-B*5701 was increased to 100% for white subjects and the entire study population. 27 The specificity of HLA-B*5701 was 96-98% for both groups. Approximately 60% of patients with the HLA-B*5701 allele developed ABC HSR versus less than 5% of patients who did not have the allele. Based on these performance characteristics, if 100 white patients undergo HLA-B*5701 screening, 6 patients will be HLA-B*5701 positive and 4 of these 6 patients would develop ABC HSR if ABC was initiated. Sensitivity could not be calculated for immunologically confirmed ABC HSR in black subjects because none of the three clinically suspected cases were skin patch test positive. Few black subjects were enrolled and no HLA-B*5701-positive black subjects received ABC. The specificity of HLA-B*5701 in black subjects was 100% for both ABC HSR end points. The specificity of skin patch testing was investigated in the first 100 ABC-tolerant patients who completed the study; no ABC-tolerant patient had a positive patch test reaction, so the specificity of skin patch testing was estimated to be 100%. Finally, costeffectiveness data are being analyzed from the PREDICT-1 study to evaluate the impact of HLA-B*5701 screening on costs associated with ABC HSR (for example, extra clinic visits, emergency room visits, hospitalizations).
A second study, SHAPE (ABC107442), was designed and conducted concurrently with PREDICT-1 to address the question of generalizability of HLA-B*5701 to non-white HIV patient populations. Because the rate of ABC HSR in patients of African descent is lower than the rate observed in Caucasians and the carriage frequency of HLA-B*5701 in patients of African descent is reduced as well, a prospective investigation of the impact of prospective HLA-B*5701 screening on ABC HSR rate in black subjects was not logistically feasible because of the sample size needed. SHAPE was a retrospective, case-control investigation of A total of 1956 ABC-naive, HIV-infected subjects were randomized 1:1 to a standard of care study arm or a prospective pharmacogenetic (PGx) screening arm. HLA-B*5701 status was prospectively determined for subjects in the prospective PGx screening arm and retrospectively determined for subjects in the standard of care arm. All subjects in the standard of care arm and subjects in the PGx screening arm who were HLA-B*5701 negative initiated ABC-containing therapy. ABC HSR was monitored throughout the 6-week observation period. Rates of clinically suspected ABC HSR and immunologically confirmed ABC HSR (that is, clinically suspected ABC HSR plus a positive ABC skin patch test reaction) were compared between the two study arms. ABC, abacavir; HLA, human leukocyte antigen; HSR, hypersensitivity. the sensitivity and specificity of HLA-B*5701 in US white and black HIV patients with clinically diagnosed ABC HSR cases with a positive ABC skin patch test result and ABC-tolerant controls without evidence of ABC HSR ( Figure 3 ). 28 Skin patch testing was used to identify immunologically confirmed cases of ABC HSR.
In self-reported white subjects, the sensitivity of HLA-B*5701 was 44% (57 of 130) when ABC HSR was defined by clinical diagnosis alone and was 100% (42 of 42) for clinically suspected, skin patch test-positive ABC HSR (Table 4 ). In self-reported black subjects, the sensitivity of HLA-B*5701 was 14% (10 of 69) when ABC HSR was defined by clinical diagnosis alone and was 100% (5 of 5) when the ABC HSR diagnosis included a positive skin patch test. The specificity of HLA-B*5701 was 96 and 99% in white and black ABC-tolerant patients, respectively. These performance characteristics for HLA-B*5701 derived from the SHAPE study in clinically diagnosed ABC HSR cases (that is, cases defined without patch test results) were very similar to the results observed in GSK's earlier retrospective PGx studies.
Importantly from an ABC HSR diagnosis perspective, skin patch test-negative patients were observed among patients who presented with ABC HSR symptoms and who were HLA-B*5701 positive. In the PREDICT-1 study, among 29 white clinically diagnosed ABC HSR cases who were HLA-B*5701 positive and had a valid skin patch test result, 6 (21%) were skin patch test negative. In the SHAPE study, the numbers of HLA-B*5701 positive ABC HSR cases with negative skin patch test results in white and black subjects were 15 of 57 (26%) and 5 of 10 (50%), respectively. While the observation of skin patch test-negative, HLA-B*5701-positive ABC HSR cases might be attributed to several factors, including operator error, concurrent medicines that might mask a positive patch reaction or false attribution of HSR-like symptoms associated with concurrent medicines/ medical conditions to ABC HSR, a potential medically concerning explanation is that skin patch testing fails to detect ABC HSR in a subset of patients. GSK holds the position that while ABC skin patch testing was a useful adjunct for PGx research purposes and provided value for determining the performance characteristics of HLA-B*5701, patch testing should not be incorporated into clinical practice because results could be misleading and reinitiation of ABC in a patch test-negative individual could put such a patient at risk for a life-threatening ABC HSR.
What happens next with the ABC HSR PGx results?
Results from the SHAPE study and supportive data from study CNA30032 in self-reported Hispanic and Thai populations support the hypothesis that the association between HLA-B*5701 and ABC HSR exists across racial populations. The PREDICT-1 study results clearly demonstrate clinical utility in prospective HLA-B*5701 screening on the incidence of ABC HSR in a randomized clinical trial. Together with supportive but uncontrolled reports from individual clinics on the utility of HLA-B*5701 screening, these study results represent the clearest evidence of the value of HLA-B*5701 PGx screening in avoidance of a potentially serious adverse drug reaction. In the PREDICT-1 study, Figure 3 SHAPE study design. SHAPE was a retrospective case-control study to evaluate the sensitivity and specificity of HLA-B*5701 for ABC HSR within self-reported black and white subjects in the United States (Study ABC107442, ClinicalTrials.gov identifier: NCT00373945). All cases underwent skin patch testing and provided a blood sample for HLA-B*5701 determination. Clinical data were collected on the timing and symptoms of ABC HSR. Two case definitions were used in this study-clinically suspected ABC HSR and immunologically confirmed ABC HSR (that is, clinically suspected ABC HSR and a positive ABC skin patch test result). Racially matched controls were retrospectively identified from subjects who received ABC in a previous clinical study without evidence of ABC HSR and who provided written informed consent and a blood sample for PGx research. ABC, abacavir; HLA, human leukocyte antigen; HSR, hypersensitivity; PGx, pharmacogenetics. approximately 60% of patients with the HLA-B*5701 allele developed clinically suspected ABC HSR compared with 4% of patients who did not have the allele. 27 The estimated incidence of HSR reaction confirmed by skin patch testing is 48% in patients with the allele compared with 0% of patients who did not have the allele. 27 That means that while HLA-B*5701 is a predictive marker for ABC HSR, other genetic markers or other non-genetic factors are likely required for manifestation of ABC HSR. To improve the benefit-to-risk ratio of ABC for all HIV patients through PGx screening, some patients who may be able to receive ABC without experiencing HSR could be excluded from ABC therapy. Furthermore, it must be noted that PGx screening is unlikely to completely eliminate clinically suspected ABC HSR due the nature of HIV disease, comorbid medical conditions and adverse events associated with concomitant medicines that a patient may receive in combination with ABC. Thus, the highly effective clinical risk-management plan currently in place for ABC must continue. Integration of GSK's data on HLA-B*5701 screening into medical practice will require education of HIV health-care providers, patients, payers and clinical laboratories that offer HLA genotyping services. GSK is working in partnership with international regulatory authorities and HIV guideline committees to promote clear and consistent guidance about the role of HLA-B*5701 screening in the care of patients living with HIV disease. European and US HIV treatment guidelines recently have been updated to recommend HLA-B*5701 screening prior to initiation of an ABCcontaining regimen. 29, 30 Should HLA-B*5701 screening be recommended and, if so, how will that recommendation be implemented around the world? Generally yes; however, a number of considerations need to be addressed. These include the effectiveness of the current risk-management plan and how prospective (not retrospective) PGx screening would be interwoven into clinical risk management, availability of reliable HLA-B*5701 testing methods along with clear and timely interpretation of HLA-B*5701 results for the health-care provider, the allele frequency of HLA-B*5701, which varies in different racial groups, and the cost-effectiveness of HLA-B*5701 screening (that is, numbers of patients needed to be screened to avoid an ABC HSR).
Hypersensitivity to ABC PGx experiments still continue. However, it has been and continues to be a remarkable journey with very significant clinical impactspanning an 8-year period-during which time dramatic progress was made in scientific knowledge and technology. This research took place over a period of great technological advancement, but the basic experimental approach of generating preliminary PGx data to form a PGx hypothesis and then prospectively testing the hypothesis has provided the robust confirmation necessary for this and other clinical applications; clearly HLA-B*5701 screening identifies patients at very high risk for ABC HSR. This early example of PGx marker discovery, replication and validation of clinical utility to address an important drug safety question is certain to be dissected and judged by the scientific community. It was important to put GSK's decision-making process and perspective into the public record, as such discussions occur to enable other researchers to learn from this successful PGx investigation.
Note: All patients who participated in the clinical trials described in this article provided written informed consent before any study-related procedures were conducted.
